ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2012 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
antibody-based anticancer products, today announced that the Company
will host a conference call at
8:00 a.m. ET on
Friday, January 27, 2012,
to discuss ImmunoGen's financial results for the three-month period
ended
December 31, 2011 – the second quarter of the Company’s 2012
fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-312-1231. Passcode: 5537853.
The call also may be accessed through the Investor Information section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through February 3, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to
deliver one of ImmunoGen's proprietary cancer-cell killing agents
specifically to tumor cells. There are now numerous TAP compounds in
clinical development with a wealth of clinical data reported.
ImmunoGen’s collaborative partners include Amgen, Bayer HealthCare
Pharmaceuticals, Biotest, Lilly, Novartis, Roche, and Sanofi. The most
advanced compound using ImmunoGen's TAP technology, trastuzumab
emtansine (T-DM1), is in Phase III testing through the Company's
collaboration with Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
Source: ImmunoGen, Inc.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153